undamentalytics Newsletter

Bradsher Neal C: insider trades

Director, 10% owner at 3 companies we cover. 31 open-market purchases and 2 sales not made under a pre-set plan, reported from August 2, 2012 to February 12, 2026.

Would copying Bradsher Neal C’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 18 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on August 3, 2012 into $5,965 by November 2, 2026, −3.6% a year. The copy held shares only 61% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $33,991, +9.0% a year (the S&P 500 held throughout made $69,383, +14.6% a year). Beta against the index was 0.68. Twelve months after each report, the average purchase was −1.2% against the S&P 500 (median −5.1%), and 44% beat it. Measured from the trade date, the insider’s own timing, the average was +10.0%. After their sales, the shares moved −55.3% against the index over 12 months on average (a negative figure means selling was the right call); 100% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$20.0k$40.0k$60.0k 20122014201620182020202220242026 $69.4k$34.0k$6.0k
Copying Bradsher Neal CS&P 500, same days investedS&P 500, held throughout $10,000 copying Bradsher Neal C’s open-market purchases from August 3, 2012, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
−3.6%
S&P 500, same days invested
+9.0% (held throughout +14.6%)
Time in shares
61%
Sharpe ratio (S&P 500)
0.12 (0.80)
Biggest drop (S&P 500)
−88% (−34%)
Market sensitivity (beta)
0.68
Purchases copied
22

Trade by trade

Bradsher Neal C: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 22 −0.6% −15.0% 41% 9 −0.46 0.66 No reliable evidence
Purchases, 6 months after the report 22 +14.2% +6.7% 55% 9 0.41 0.69 No reliable evidence
Purchases, 12 months after the report 18 −1.2% −5.1% 44% 8 0.01 0.99 No reliable evidence
Purchases, 12 months after the trade 17 +10.0% −6.6% 47% 7 1.20 0.27 No reliable evidence
Sales, 3 months after the report 2 +2.8% +2.8% 50% 1 — — Not enough years
Sales, 12 months after the report 2 −55.3% −55.3% 100% 1 — — Not enough years
Sales, 12 months after the trade 2 −50.7% −50.7% 100% 1 — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Staar Surgical Co STAA —202August 2, 2012January 13, 2026
Lineage Cell Therapeutics, Inc. LCTX —60March 29, 2013March 25, 2022
Insight Molecular Diagnostics Inc. IMDX —50November 15, 2019February 12, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
February 12, 2026February 10, 2026 IMDX Purchase $2,999,999 +6.4%not yetnot yet
January 13, 2026January 9, 2026 STAA Purchase $606,044 +10.9%not yetnot yet
January 8, 2026January 6, 2026 STAA Purchase $8,818,095 +22.2%not yetnot yet
November 21, 2025November 19, 2025 STAA Purchase $41,061,615 −26.8%not yetnot yet
April 10, 2025April 8, 2025 STAA Purchase $2,866,871 −16.4%+14.7%+36.8%
March 28, 2025March 26, 2025 STAA Purchase $1,983,904 −14.2%−8.8%−11.0%
February 14, 2025February 12, 2025 STAA Purchase $6,276,178 +18.2%−5.7%−16.6%
January 16, 2025January 14, 2025 STAA Purchase $630,738 −12.1%−23.6%−23.4%
November 14, 2023November 10, 2023 STAA Purchase $1,140,045 −26.0%−58.1%−50.7%
November 9, 2023November 7, 2023 STAA Purchase $9,663,814 −24.5%−50.7%−48.2%
November 6, 2023November 2, 2023 STAA Purchase $10,796,758 −27.7%−48.2%−53.1%
September 7, 2023September 5, 2023 STAA Purchase $7,868,640 −31.8%−56.2%−49.7%
March 25, 2022March 23, 2022 LCTX Purchase $1,317,145 not yetnot yetnot yet
February 9, 2021February 5, 2021 STAA Sale $31,324,185 −14.8%−54.8%−53.3%
January 28, 2021January 26, 2021 STAA Sale $82,075,796 +20.4%−55.8%−48.1%
January 22, 2021January 20, 2021 IMDX Purchase $4,994,158 −23.5%−85.2%not yet
April 28, 2020April 24, 2020 IMDX Purchase $2,383,500 not yetnot yetnot yet
January 6, 2020January 2, 2020 IMDX Purchase $3,005,567 not yetnot yetnot yet
November 15, 2019November 13, 2019 IMDX Purchase $2,000,001 not yetnot yetnot yet
May 3, 2019May 3, 2019 STAA Purchase $2,223,000 +21.4%+39.5%+47.4%
October 17, 2017October 13, 2017 LCTX Purchase $6,999,998 not yetnot yetnot yet
August 24, 2017August 22, 2017 LCTX Purchase $26,000 not yetnot yetnot yet
June 30, 2016June 28, 2016 STAA Purchase $74,115 +58.5%+64.2%+84.0%
May 25, 2016May 23, 2016 STAA Purchase $401,728 +58.8%+53.7%+57.7%
May 16, 2016May 12, 2016 STAA Purchase $1,846,842 +68.8%+65.7%+50.1%
February 9, 2016February 5, 2016 STAA Purchase $573,347 +6.8%+30.2%+36.8%
September 29, 2015September 25, 2015 STAA Purchase $2,202,993 −15.8%+3.6%+14.2%
November 19, 2014November 17, 2014 STAA Purchase $1,639,503 −22.2%−4.5%−6.6%
November 7, 2014November 5, 2014 STAA Purchase $713,600 −25.5%−8.5%−9.8%
June 18, 2014June 16, 2014 LCTX Purchase $2,500,000 not yetnot yetnot yet
May 9, 2014May 8, 2014 LCTX Purchase $732,000 not yetnot yetnot yet
March 29, 2013March 28, 2013 LCTX Purchase $762,000 not yetnot yetnot yet
August 2, 2012July 31, 2012 STAA Purchase $1,524,815 −17.8%+55.6%+112.8%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Bradsher Neal C traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.